Vanda Pharmaceuticals is preparing to commercially launch BYSANTI during the second half of 2026 following FDA approval for bipolar I disorder and schizophrenia, with the therapy protected by data exclusivity into 2031 and patents extending as far as May 2044.
BYSANTI, or milsaperidone, received FDA approval during Q1 2026. Vanda expects to launch the product in the second half of the year as it builds a broader commercial portfolio alongside Fanapt, HETLIOZ, PONVORY and recently launched NEREUS.
The product has U.S. data exclusivity through February 20, 2031 and multiple patents, with the latest currently scheduled to expire on May 31, 2044. The lengthy intellectual-property runway could provide Vanda with substantial time to commercialize the therapy if the product achieves market adoption.
BYSANTI is also being developed beyond its initial approved indications. A Phase III trial is evaluating the treatment as a once-daily adjunctive therapy for major depressive disorder, with results expected during the first half of 2027.
The launch comes as Vanda’s established Fanapt franchise continues to expand. Q2 Fanapt net product sales increased 23% year-over-year to $36 million, while total prescriptions increased 31% and new-to-brand prescriptions grew 32%.
Compared with Q2 2024, Fanapt total prescriptions have increased 62% and new-to-brand prescriptions have risen 300% following the product’s expansion into bipolar disorder.
Vanda generated total Q2 net product sales of $50.5 million, down 4% from $52.6 million. That figure excludes approximately $7 million of HETLIOZ revenue for orders shipped June 29 but received July 1, which will instead be recognized during Q3.
Vanda is simultaneously advancing a large late-stage pipeline. The company expects three Phase III readouts before year-end 2026, involving NEREUS for GLP-1-induced vomiting, VQW-765 for social anxiety disorder and HETLIOZ for delayed sleep phase disorder.
Another potential product, Quimilza, is under FDA review for generalized pustular psoriasis with a PDUFA target date of December 12, 2026.
Vanda held $170 million of cash, cash equivalents and marketable securities at June 30. Management believes its current resources and anticipated product revenue will fund operations through at least the end of 2027.
The company has spent heavily on Phase III trials, manufacturing and preparations for multiple commercial launches. As those programs mature, Vanda expects operating expenses to begin declining toward the end of 2026 and more substantially throughout 2027.
KEY QUOTES:
“With BYSANTI approved and on track for launch in the second half of 2026, a December 2026 PDUFA date for Quimilza and multiple late-stage clinical trial results expected before year-end, we believe Vanda is well positioned for meaningful commercial expansion and pipeline value creation.”
“As our Phase III programs, launch preparations, and commercial supply manufacturing near completion, we expect operating expenses to begin moderating later this year and more significantly in 2027. Our current resources, together with anticipated product revenues, provide a solid foundation to advance our objectives through at least the end of 2027.”
Mihael H. Polymeropoulos, M.D., President, CEO and Chairman of Vanda Pharmaceuticals
